San Francisco–based Decagon, which develops conversational AI agents, has raised $250 million in a Series D round led by Coatue and Index Ventures. The deal underscores the continued flow of large-scale capital into artificial intelligence as investors double down on the sector’s growth potential.
Biotech also drew strong interest. Tenpoint Therapeutics, focused on treatments for degenerative eye diseases, secured $85 million in Series B funding led by Janus Henderson, EQT Nexus, Hillhouse and the British Business Bank, alongside a $150 million debt facility from Hercules Capital. Elsewhere, Belgian biotech Agomab Therapeutics is preparing to go public, targeting a valuation of about $780 million at the midpoint of its proposed price range.lion from investors including AMD, Meta and Intel Capital.
